Orthofix Medical Inc. Enters Material Definitive Agreement
Ticker: OFIX · Form: 8-K · Filed: Apr 22, 2024 · CIK: 884624
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Orthofix just signed a big deal, details TBD.
AI Summary
Orthofix Medical Inc. announced on April 19, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement or any associated dollar amounts or dates beyond the report date.
Why It Matters
This filing indicates a significant new contract or partnership for Orthofix Medical Inc., which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its terms and potential impact.
Key Players & Entities
- Orthofix Medical Inc. (company) — Registrant
FAQ
What is the nature of the Material Definitive Agreement entered into by Orthofix Medical Inc.?
The filing states that Orthofix Medical Inc. entered into a Material Definitive Agreement on April 19, 2024, but does not specify the details of the agreement.
When was the Material Definitive Agreement reported?
The agreement was reported on April 19, 2024.
Does the filing provide any financial figures related to this agreement?
No, the filing does not provide any specific dollar amounts or financial figures related to the Material Definitive Agreement.
What is Orthofix Medical Inc.'s principal executive office address?
Orthofix Medical Inc.'s principal executive offices are located at 3451 Plano Parkway, Lewisville, Texas 75056.
Is there any information about former names or addresses of Orthofix Medical Inc. in this filing?
The filing mentions that the former company name was ORTHOFIX INTERNATIONAL N V and the date of name change was July 8, 1997, but does not indicate any change in address since the last report.
Filing Stats: 765 words · 3 min read · ~3 pages · Grade level 12.5 · Accepted 2024-04-19 18:58:30
Key Financial Figures
- $0.10 — nge on which registered Common stock, $0.10 par value per share OFIX Nasdaq Glo
Filing Documents
- ofix-20240419.htm (8-K) — 42KB
- ofix-ex10_1.htm (EX-10.1) — 74KB
- 0000950170-24-046161.txt ( ) — 233KB
- ofix-20240419.xsd (EX-101.SCH) — 23KB
- ofix-20240419_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On April 19, 2024, Orthofix Medical Inc. (the "Company") entered into an amendment (the "Amendment") to that certain cooperation agreement, dated December 11, 2023 (the "Cooperation Agreement"), by and among Engine Capital, L.P., Engine Jet Capital, L.P., Engine Lift Capital, LP, Engine Capital Management, LP, Engine Capital Management GP, LLC, Engine Investments, LLC, Engine Investments II, LLC and Arnaud Ajdler (collectively, the "Engine Group") and the Company. The Amendment provides that if the Board determines in good faith after consulting with counsel that it would violate the Board's fiduciary duties under applicable law for the Board to recommend, support and solicit proxies for the election of any of Alan L. Bazaar, Michael M. Finegan or Charles R. Kummeth (each, a "Specified Director") at the Company's 2024 annual meeting of shareholders (the "2024 Annual Meeting") in the same manner as for the Company's other nominees at the 2024 Annual Meeting, then the Board will not be required to recommend, support and solicit proxies for the applicable Specified Director, and the Engine Group will be permitted to solicit proxies in favor of any such Specified Director, make statements and announcements, and otherwise engage in communications with shareholders in connection with such solicitation. In addition, the Amendment confirms that certain other obligations of the Company under the Cooperation Agreement are subject to the exercise of the Board's fiduciary duties under applicable law, and provides that if the Company fails to take specified actions as a result of the Board determining in good faith after consultation with counsel that taking actions would violate the Board's fiduciary duties, that standstill provisions currently applicable to the Engine Group would cease to remain in effect. The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by refe
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 10.1 First Amendment to Cooperation Agreement, entered into on April 19, 2024, by and among Orthofix Medical Inc. Engine Capital, L.P., Engine Jet Capital, L.P., Engine Lift Capital LP, Engine Capital Management, LP, Engine Capital Management GP, LLC, Engine Investments, LLC, Engine Investments II, LLC and Arnaud Ajdler. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Orthofix Medical Inc. Date: April 22, 2024 By: /s/ Kimberley Elting President, Global Orthopedics